Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer

被引：0
|
作者：
Gyorffy, B.
Ocana, A.
Herman, P.
Hatzis, C.
Pandiella, A.
Pusztai, L.
机构：
[1] Yale Univ, New Haven, CT 06520 USA
[2] Servicoio Salud Castilla la Mancha, Albacete, Spain
[3] MTA TTK, Budapest, Hungary
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-49
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
    van Olmen, Josefien P.
    Jacobs, Chaja F.
    Bartels, Sanne A. L.
    Loo, Claudette E.
    Sanders, Joyce
    Drukker, Caroline A.
    van Duijnhoven, Frederieke H.
    Kok, Marleen
    BREAST, 2024, 75
  • [43] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Sung Gwe Ahn
    Yoon Jin Cha
    Soon June Bae
    Chanik Yoon
    Hak Woo Lee
    Joon Jeong
    BMC Cancer, 18
  • [44] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Ahn, Sung Gwe
    Cha, Yoon Jin
    Bae, Soon June
    Yoon, Chanik
    Lee, Hak Woo
    Jeong, Joon
    BMC CANCER, 2018, 18
  • [45] A Novel 5-gene Score to Predict Complete Pathological Response to Neoadjuvant Chemotherapy in ER-Positive/HER2-Negative Breast Cancer
    Oshi, Masanori
    Angarita, Fernando A.
    Tokumaru, Yoshihisa
    Yan, Li
    Endo, Itaru
    Takabe, Kazuaki
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S348 - S348
  • [46] A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Oshi, Masanori
    Gandhi, Shipra
    Angarita, Fernando A.
    Kim, Tae Hee
    Tokumaru, Yoshihisa
    Yan, Li
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (07): : 3611 - +
  • [47] Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
    Pelaez-Garcia, Alberto
    Yebenes, Laura
    Berjon, Alberto
    Angulo, Antonia
    Zamora, Pilar
    Sanchez-Mendez, Jose Ignacio
    Espinosa, Enrique
    Redondo, Andres
    Heredia-Soto, Victoria
    Mendiola, Marta
    Feliu, Jaime
    Hardisson, David
    PLOS ONE, 2017, 12 (09):
  • [48] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675
  • [49] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
    Friedman-Eldar, Orli
    Ozmen, Tolga
    Reyes, Fernando Valle
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susane B.
    Moller, Mecker
    Franceschi, Dido
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
  • [50] Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
    Pascual, Javier
    Gil-Gil, Miguel
    Proszek, Paula
    Zielinski, Christoph
    Reay, Alistair
    Ruiz-Borrego, Manuel
    Cutts, Rosalind
    Ciruelos Gil, Eva M.
    Feber, Andrew
    Munoz-Mateu, Montserrat
    Swift, Claire
    Bermejo, Begona
    Herranz, Jesus
    Margeli Vila, Mireia
    Anton, Antonio
    Kahan, Zsuzsanna
    Csoeszi, Tibor
    Liu, Yuan
    Fernandez-Garcia, Daniel
    Garcia-Murillas, Isaac
    Hubank, Michael
    Turner, Nicholas C.
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4166 - 4177
12345